Home » GTC BIOTHERAPEUTICS AND LEO PHARMA TO DEVELOP AND MARKET ATRYN IN EUROPE, THE MIDDLE EAST, AND CANADA
GTC BIOTHERAPEUTICS AND LEO PHARMA TO DEVELOP AND MARKET ATRYN IN EUROPE, THE MIDDLE EAST, AND CANADA
GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and LEO Pharma A/S ("LEO") have entered into a collaboration agreement to develop and market ATryn(R) for markets in Europe, the Middle East, and Canada. ATryn(R) is GTC's recombinant form of human antithrombin, a plasma protein with anticoagulant and anti-inflammatory properties. The agreement includes $73 million (USD) in potential milestone payments to GTC for meeting regulatory, clinical and sales goals.
Business Wire (http://www.biospace.com/news_story.aspx?StoryId=1245)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May